97336 ⎘
Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS
#302Antibodies directed against lymphocyte activation gene 3 (LAG-3)
#303Treatment of ocular neovascularization using anti-VEGF proteins
#304Polypeptides
#305Bispecific multivalent fusion proteins
#306IL15/IL15Rα heterodimeric Fc-fusion proteins
#307Anhydrous hydrogel composition and delivery system
#308BCMA chimeric antigen receptors
#309Binding-triggered transcriptional switches and methods of use thereof
#310Single-chain CD40-receptor agonist proteins
#311BINDING MEMBERS OF INTERLEUKIN-4 RECEPTOR ALPHA (IL4-Ra)
#312ANTAGONISTS OF IL-20 FAMILY OF CYTOKINES AND THEIR USE
#313Methods for expanding immune cells
#314Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
#315Recombinant self-assembling protein comprising target-oriented peptide and use thereof
#316Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins
#317ANTI-ACTIVIN A ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION
#318Methods, arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy
#319Anti APRIL (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer
#320Methods and compositions for transducing lymphocytes and regulating the activity thereof
#321COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
#322Pertussis vaccines and methods of making and using
#323Methods of treating liver conditions using Notch2 antagonists
#324Angiopoietin 2, VEGF dual antagonists
#325METHODS AND COMPOSITIONS PERTAINING TO HUMAN CEREBRAL CAVERNOUS MALFORMATIONS
#326Glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) single-chain fusion polypeptides
#327Human Notch1 decoys
#328Methods of treating cervical cancer
#329TREATMENT OF IL-17 MEDIATED DISEASE BY BLOCKING SEFIR-SEFIR INTERACTIONS
#330Chimeric Receptors with 4-1BB Stimulatory Signaling Domain
#331Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#332Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
#333Anti PD-1 antibodies
#334Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent
#335Hydrogel microspheres containing peptide ligands for growth factor regulation in blood products
#336Systems and methods for obtaining information associated with an anatomical sample using optical microscopy
#337Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies
#338Anti-PDGFR-beta antibodies and uses thereof
#339Use of a VEGF antagonist to treat angiogenic eye disorders
#340Anti-inflammatory molecules with tissue-targeting functions
#341Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#342ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING OR PREVENTING BREAST CANCER
#343INTERLEUKIN-15 SUPERAGONIST SIGNIFICANTLY ENHANCES GRAFT-VERSUS-TUMOR ACTIVITY
#344Anti-PVRIG antibodies and methods of use
#345Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
#346GITRL-collectin fusion proteins and encoding nucleic acids
#347METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
#348COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY OF IGG-DECOY RECEPTOR FUSION PROTEINS
#349Process for preparation of secretory IgA and secretory IgM
#350Pharmaceuticals in joint-linker configurations for treating pathological blood clots
#351Biomolecule-releasing cell and selection thereof by means of a surface protein
#352Anti-PVRIG antibodies and methods of use
#353Anti-MCAM antibodies and associated methods of use
#354Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
#355IL-15 and IL-15R\alpha sushi domain based immunocytokines
#356CD27 single chain molecules and encoding nucleic acids
#357SOLUBLE CTLA-4 MOLECULES AND DERIVATIVES THEREOF FOR TREATMENT OF MINIMAL CHANGE DISEASE
#358Binding-triggered transcriptional switches and methods of use thereof
#359Anti-PVRIG antibodies and methods of use
#360METHODS OF TREATING NEUROENDOCRINE TUMORS USING FRIZZLED-BINDING AGENTS
#361Soluble CD33 for treating myelodysplastic syndromes (MDS)
#362Molecular constructs for treating tumors
#363METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR
#364CD40L collectin fusion proteins and encoding nucleic acid molecules
#365Insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands
#366NOGO Receptor Antagonists
#367Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
#368Development of masked therapeutic antibodies to limit off-target effects
#369Growth hormone secretagogue receptor based protein
#370Anti-PDGFR-beta antibodies and uses thereof
#371Method of identifying an agent that promotes bone growth or increases bone density
#372ACTRIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS
#373Recombinant self-assembling protein comprising target-oriented peptide and use thereof
#374Notch pathway inhibition
#375Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide
#376METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRANSPLANT REJECTION
#377B7-H4 fusion proteins and methods of use thereof
#378Glycosylated VEGF decoy receptor fusion protein
#379Methods and compositions using a Klotho-FGF23 fusion polypeptide
#380Method of treating eye disease using glycosylated VEGF decoy receptor fusion protein
#381Compounds for treating neurodegenerative proteinopathies
#382Chimeric receptors with 4-1BB stimulatory signaling domain
#383BTNL9 proteins, nucleic acids, and antibodies and uses thereof
#384Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
#385Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same
#386IL-33R and IL-1RAcP fusion proteins
#387Compounds and methods for treating pain
#388Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
#389Broad spectrum ErBB ligand binding molecules and methods for preparing and using them
#390Biomarker TFF1 for predicting effect of C-MET inhibitor
#391AXL TYROSINE KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME
#392Deimmunized serum-binding domains and their use in extending serum half-life
#393Inhibitors of the CD95 signaling pathway for treatment of MDS
#394Chimeric receptors and uses thereof in immune therapy
#395Trail collectin fusion proteins
#396CD147 as receptor for pilus-mediated adhesion of to vascular endothelia
#397CTLA4 fusion proteins for the treatment of diabetes
#398Serpin fusion polypeptides and methods of use thereof
#399Methods for binding members of interleukin-4 receptor α (IL-4Rα)
#400T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF
#401Compositions comprising secretory-like immunoglobulins
#402TGFB type II-type III receptor fusions
#403Chimeric molecule involving oligomerized FasL extracellular domain
#404Anhydrous hydrogel composition and delivery system
#405Treatment of ocular neovascularization using anti-VEGF proteins
#406Soluble TCR molecules and methods of use
#407Chimeric receptors with 4-1BB stimulatory signaling domain
#408Composition for improving skin conditions, containing extracellular domain of human bone morphogenetic protein receptor 1a as active ingredient
#409Human Notch1 decoys
#410IL-33 antagonists and uses thereof
#411Fusion protein for suppressing cancer cell growth and suppressing vasculogenesis, and anticancer composition comprising same
#412Rapid clearance of antigen complexes using novel antibodies
#413Methods of promoting fat loss comprising administering an ALK7 inhibitor
#414DDR1-binding agents and methods of use thereof
#415Multimeric constructs
#416Anti-PDGFR-beta antibodies and uses thereof
#417Recombinant immunotoxin targeting mesothelin
#418Methods of treating disease with FGFR1 fusion proteins
#419VISTA modulators for diagnosis and treatment of cancer
#420Anti-VEGF-C antibodies and methods using same
#421Binding members for interleukin-4 receptor alpha (IL-4Rα) - 173
#422FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC
#423Antibodies against a proliferating inducing ligand (APRIL) and methods of use thereof
#424Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
#425Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
#426Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides
#427High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins
#428METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS
#429ACTRIIB-FC polynucleotides, polypeptides, and compositions
#430Polynucleotides encoding FGFR1-IIIc ECD fusion proteins
#431Development of masked therapeutic antibodies to limit off-target effects
#432Compositions comprising ALK1-ECD protein
#433METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
#434Wnt antagonists and methods of treatment and screening
#435TNF-A and TWEAK dual antagonist for the prophylaxis and treatment of autoimmune diseases
#436FGFR2-IIIb fusion proteins and methods of making them
#437METHODS OF TREATING INFLAMMATION USING SOLUBLE IL-17RA/RC FUSION PROTEINS
#438Chimeric receptors with 4-1BB stimulatory signaling domain
#439Method of inducing an antiviral immune response against HIV-1 utilizing chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics
#440Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
#441B7-H4 fusion proteins and methods of use thereof
#442Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
#443Broad spectrum ErbB ligand binding molecules and methods for preparing and using them
#444CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#445Methods of treating cancer by administering an Axl ligand-binding portion of an Axl tyrosine kinase receptor extracellular domain
#446Antibodies against a proliferating inducing ligand (APRIL) and methods of use thereof
#447Modified soluble FGF receptor Fc fusions method
#448Methods of promoting fat loss comprising administering an ALK7 inhibitor
#449Receptor activator of NF-kappaB
#450Methods and compositions for the inhibition of transplant rejection
#451Binding members for interleukin-4 receptor alpha (IL-4Ra) - 173
#452Cytokine antagonists for neurological and neuropsychiatric disorders
#453Specific binding agents of human angiopoietin-2
#454Soluble PD-1 variants, fusion constructs, and uses thereof
#455MODIFIED EGFR ECTODOMAIN
#456Methods and compositions for inhibiting viral entry into cells
#457Methods of treating inflammation using soluble IL-17RA/RC fusion proteins
#458FGFR1C ANTIBODY COMBINATIONS
#459Method for promoting bone growth using activin-actriia antagonists
#460Anti-VEGF-C antibodies and methods using same
#461Cells and methods for producing blocking antibodies to human RANKL
#462Therapeutic antibodies binding IL12Rβ1
#463Anticoagulant fusion protein anchored to cell membrane
#464EXPANSION OF NK CELLS AND THERAPEUTIC USES THEREOF
#465BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS
#466Wnt Antagonists and Methods of Treatment and Screening
#467NUCLEIC ACID ENCODING FUSION POLYPEPTIDES THAT PREVENT OR INHIBIT HIV INFECTION
#468DDR1-binding agents and methods of use thereof
#469AMINO ACID SEQUENCES DIRECTED AGAINST GROWTH FACTOR RECEPTORS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH GROWTH FACTORS AND THEIR RECEPTORS
#470ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them
#471Bifunctional molecules for inactivating HIV and blocking HIV entry
#472Multimeric constructs
#473COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS
#474BLOCKERS OF LIGHT, LTalpha1beta2 AND LTalpha2beta1 OR ITS RECEPTOR LTbetaR FOR THE PREVENTION AND TREATMENT OF CHRONIC HEPATITIS AND OTHER LIVER DISEASES
#475Antagonists of ligands and uses thereof
#476Kits for detecting rank
#477Anti-CD147 antibodies, methods and uses
#478Methods for the treatment of radiation or chemotherapy-induced tissue damage
#479DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES
#480TGF-Beta Antagonist Multi-Target Binding Proteins
#481Single-chain TNFSF fusion polypeptides
#482Multi-Specific Binding Proteins Targeting B Cell Disorders
#483INSULIN-LIKE GROWTH FACTOR FUSION PROTEINS
#484TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS
#485Fully human anti-human NKG2D monoclonal antibodies
#486ANTI-VEGF-C ANTIBODIES AND METHODS USING SAME
#487PURIFIED IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF THEIR PURIFICATION
#488LEPTIN FUSION PROTEINS
#489Method of inhibiting osteoclast activity
#490Anti-viral fusion peptides
#491ADAPTER MOLECULE FOR THE DELIVERY OF ADENOVIRUS VECTORS
#492T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THERE OF
#493Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes
#494Soluble IL-17RA/RC fusion proteins and related methods
#495Axl fusion proteins as Axl tyrosine kinase inhibitors
#496COMPOSITIONS AND METHODS FOR DISRUPTING THE FUNCTION OF THE TRANSCRIPTIONAL REPRESSOR COMPONENT Sin3A-PAH2 DOMAIN TO INDUCE DIFFERENTIATION AND GROWTH INHIBITION IN BREAST CANCER
#497REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS
#498Regulated apoptosis
#499ALK7 AND MYOSTATIN INHIBITORS AND USES THEREOF
#500VIRAL VECTOR SYSTEM, A COMPOSITION COMPRISING THE VIRAL VECTOR SYSTEM AND ITS USE
#501Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
#502Chimeric HIV-1 Glycoproteins and Their Biological Applications
#503Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#504USE OF ESTROGEN AND ANDROGEN BINDING PROTEINS IN METHODS AND COMPOSITIONS FOR TREATING GYNAECOLOGICAL CANCERS
#505SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2
#506Notch-based fusion proteins and uses thereof
#507Actriib-Fc polynucleotides, polypeptides, and compositions
#508Products for altering IL-33 activity and methods thereof
#509MODULATION OF SIRP-ALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR
#510Methods and compositions using FGF23 fusion polypeptides
#511FUSION PROTEINS CONTAINING TWO TGF-BETA BINDING DOMAINS OF TGF-BETA TYPE II RECEPTOR
#512Collectin fusion proteins comprising TNF or trail
#513FcgammaRIIB Fusion Proteins and Compositions Thereof
#514CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#515FGFR3-IIIc fusion proteins
#516CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
#517REGULATION OF MYELINATION BY NECTIN-LIKE (NECL) MOLECULES
#518Facilitating protein solubility by use of peptide extensions
#519TOLL-LIKE RECEPTOR BINDING EPITOPE AND COMPOSITIONS FOR BINDING THERETO
#520Treatment of inflammation using BST2 inhibitor
#521Antagonist of ligands and uses thereof
#522Light targeting molecules and uses thereof
#523KIM-1 ANTAGONISTS AND USE TO MODULATE IMMUNE SYSTEM
#524Modified soluble FGF receptor Fc fusions with improved biological activity
#525NK Cell Receptor Conjugates for Treating Malignancies
#526Amelioration of Inflammatory Arthritis By Targeting the Pre-ligand Assembly Domain (Plad) of Tumor Necrosis Factor Receptors
#527CHIMERIC VACCINE ANTIGENS AGAINST THE AVIAN INFLUENZA VIRUS
#528Expression vectors
#529TLR4 decoy receptor protein
#530Pharmaceutical preparations comprising an ALK1-Fc fusion protein
#531Chimeric proteins and their use in methods to screen for sweet taste modulators
#532COMPOSITIONS AND METHODS FOR INHIBITING SHIGA TOXIN AND SHIGA-LIKE TOXIN
#533CD30 Ligand
#534Modified Fusion Polypeptides
#535Methods For Immuno-Detection Of Epitopes On Molecules And For Detection Of Interactions Of Molecules Via Fluorescent Dyes
#536Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
#537Rage protein derivatives
#538High affinity antibodies against HMGB1 and methods of use thereof
#539B7-H4 RECEPTOR AGONIST COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND AUTO-IMMUNE DISEASES
#540Use of Toll-Like Receptor 4 Antagonists for the Treatment or Prevention of Osteoarthritic Conditions
#541Methods for treating pain
#542Chemokine binding activity of viral TNF receptors and related proteins
#543Treatment and prevention of joint disease
#544Activin-ActRIIa antagonists and uses for promoting bone growth
#545Nogo receptor antagonists
#546Methods of promoting growth of muscle tissue using ALK7
#547Method for promoting bone growth using activin-ActRIIa antagonists
#548Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
#549Virus coat protein/receptor chimeras and methods of use
#550Activin-actriia antagonists and uses for treating or preventing breast cancer
#551Regulated transcription of targeted genes and other biological events
#552Specific binding agents of human angiopoietin-2
#553BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUATROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS
#554Methods for interfering with rank signaling
#555Expansion of NK cells and therapeutic uses thereof
#556Receptor based antagonists and methods of making and using
#557Chimeric soluble hyper il-11 and use thereof
#558Rage Fusion Proteins And Methods Of Use
#559Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
#560Methods of using IL-1 antagonists to treat neointimal hyperplasia
#561Nogo Receptor Antagonists
#562Fused Protein Composition
#563Soluble IL-17RA/RC fusion proteins
#564HER-2/neu fusion proteins
#565Compositions and methods of treating disease with FGFR fusion proteins
#566CD47 related compositions and methods for treating immunological diseases and disorders
#567A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
#568Method of vaccinating subjects receiving immune modulating therapy
#569Kits for detecting rank nucleic acids
#570ZTNFR14, A Tumor Necrosis Factor Receptor
#571Tie Receptor and Tie Ligand Materials and Methods for Modulating Female Fertility
#572Novel Therapeutic Fusion Proteins
#573Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
#574Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
#575Binding constructs and methods for use thereof
#576Methods, arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy
#577Multimeric constructs
#578Nucleic acids encoding chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
#579Targeting proteins to deliver therapeutic or diagnostic reagents
#580Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
#581Methods for blocking TNF-alpha activity in mammals with trimeric soluble TNF receptors
#582Treatment of Inflammatory Bowel Disease with IFN-Gamma Inhibitors
#583Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
#584Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b
#585TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH IFN-GAMMA INHIBITORS
#586Interferon-α/β binding fusion proteins and therapeutic uses thereof
#587Fusion proteins comprising tumor necrosis factor receptor
#588Chimeric cytoplasmic signalling molecules
#589Lymphocyte homing receptors
#590KIM-1 antagonists and use to modulate immune system
#591Methods and compositions for inhibiting neoplastic cell growth
#592Methods of using IL-1 antagonists to reduce C-reactive protein
#593Nk cell receptor conjugates for treating malignancies
#594Pharmaceutical compositions comprising an hiv envelope protein and cd4
#595Methods and means for targeted gene delivery
#596Specific binding agents of human angiopoietin-2
#597Olfactory receptor expression libraries and methods of making and using them
#598Modified cell line and method for expansion of NK cell
#599Regulated transcription of targeted genes and other biological events
#600Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes